BMS-309404

BMS-309404 is a potent and selective small molecule inhibitor of Fatty Acid Binding Protein 4 (FABP4), also known as adipocyte protein 2 (aP2). Developed by Bristol Myers Squibb, it acts as a competitive inhibitor that binds to the fatty acid-binding pocket of FABP4, thereby preventing the transport of fatty acids and the subsequent activation of inflammatory pathways. In research settings, BMS-309404 has demonstrated the ability to reduce macrophage foam cell formation, suppress the secretion of pro-inflammatory cytokines like IL-1β, and decrease the expression of matrix metalloproteinase-9 (MMP-9). It is primarily utilized as a pharmacological tool to investigate the role of FABP4 in metabolic and cardiovascular diseases, including atherosclerosis, type 2 diabetes, and obesity-related inflammation.